Market Snapshot
| Study Period: | 2019-2027 |
| Base Year: | 2021 |
| Fastest Growing Market: | Asia Pacific |
| Largest Market: | North America |
| CAGR: | 15.5 % |
|
Need a report that reflects how COVID-19 has impacted this market and its growth?
Market Overview
The urothelial cancer drugs market studied is projected to witness a CAGR of 15.5% over the forecast period.
The emergence of COVID-19 has had a profound impact on the urothelial cancer drugs market. For instance, according to the study published in June 2022, titled "The Impact of the COVID-19 Pandemic on Bladder Cancer Care in the Netherlands" the number of bladder cancer (BC) diagnoses fell by 14% during the first COVID-19 wave but rose back to pre-COVID levels by the end of 2020 (600 diagnoses a month). Treatment-related alterations were kept to a minimum and adhered to the revised guidelines. Additionally, as per the May 2022 updates from American Urological Association, during the peak of the COVID-19 pandemic in 2020, more than a quarter of patients with bladder cancer experienced care delays in the United States. 76,984 (27.2%) patients reported that their treatment was changed, delayed, or canceled as a result of the pandemic, including bladder cancer (27.5%). As a result of the pandemic, the urothelial cancer drug market and also diagnostics had been significantly impacted.
The urothelial cancer drug market may witness rapid growth due to the increasing awareness about bladder diseases and available therapies, along with growing healthcare expenditure and the growing burden of bladder cancer. For instance, in March 2022, the 'Don't Go Red' theme for Bladder Cancer Awareness has been declared by World Bladder Cancer Patient Coalition to raise awareness of warning signs and symptoms, as early detection is critical for enhancing long-term survival and quality of life. Such initiatives are expected to boost market growth over the forecast period.
Additionally, the increasing prevalence of bladder cancer across the world supports the market expansion over the forest period. For instance, the Global Cancer Observatory Statistics 2020 reported that bladder cancer and prostate cancer are among the top 10 high incidence cancer around the world. The same source also reported that in 2020, the estimated number of new cases of bladder cancer was 573,278, and that of prostate cancer was 1,414,259 cases among both sexes in the year 2020. Such a high incidence of cancer worldwide is propelling the market over time.
Additionally, the urothelial cancer drugs market is likely to be benefitted from better therapies being approved by prominent drug regulatory organizations. For instance, in April 2020, China National Medical Products Administration (NMPA) approved tislelizumab developed by BeiGene to treat advanced/metastatic urothelial carcinoma. Several novel treatments are predicted to see approvals, further supporting the growth of the market.
Thus, all aforementioned factors are expected to boost market growth. However, side effects associated with drugs and regulatory issues may restrain market growth.
Scope of the Report
As per the scope of the report, urothelial carcinoma, also known as transitional cell carcinoma, is a cancerous tumor of the bladder, which also spreads to other parts of the body. The urothelium comprises the lining on the inside of the bladder, urethra, and ureters. It also consists of the renal pelvis. The urothelial cancer drugs market has been segmented by treatment (chemotherapy and immunotherapy) and geography (North America, Europe, Asia Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Treatment | |
| Chemotherapy | |
| Immunotherapy |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Key Market Trends
Chemotherapy Segment is Expected to Witness the Fastest Growth Over the Forecast Period
The chemotherapy segment is expected to dominate the market, as the drugs may be used alone or in combination, depending on the purpose of their usage. The segment is driven by the rise in the adoption of chemotherapy, the rising prevalence of bladder cancer, and product launches by the key market players.
Chemotherapy is the most common form of therapeutics used to stop or slow down the growth of urothelial cancer cells. It works throughout the whole body to destroy and damage cancer cells spread to other parts of the body away from the original tumor.
As chemotherapy is considered a first-line treatment for the treatment of urothelial cancer, the segment is expected to see a surge over the forecast period. As per the study published in January 2020 titled "Efficacy and Safety of Chemotherapy Regimens in Advanced or Metastatic Bladder and Urothelial Carcinomas: An Updated Network Meta-Analysis", gemcitabine plus cisplatin (GC) and methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) have been the first-line treatments for advanced or metastatic urothelial carcinoma (AMUC).
Furthermore, as per the results of 'Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a Phase III, open-label, randomized controlled trial', published in March 2020, gemcitabine-platinum combination chemotherapy significantly improved the outcomes in patients suffering from upper tract urothelial carcinoma. Such studies are expected to aid the market growth in this segment.
Thus, all aforementioned factors are expected to boost the segment growth over the forecast period.
To understand key trends, Download Sample Report
North America Dominates the Market and Expected to Follow the Same Trend Over the Forecast Period
The North American region has been dominating the urothelial cancer drugs market. With the emergence of COVID-19, a significant impact on the urothelial cancer drugs market was also observed. As a result, organizations, such as the American College of Surgeons (ACS), have released recommendations to guide appropriately on the treatment delays.
Factors such as the presence of a large target population, increased adoption of novel therapeutics, and multiple product launches are expected to boost the growth of the market over the forecast period. For instance, as per the data of GLOBOCAN updated in 2020, about 90,000 new cases of bladder cancer were reported in North America in 2020, this number is expected to increase and reach up to 137,000 by 2040. Moreover, as per the 2022 update from the American Cancer Society on “Key Statistics for Bladder Cancer”, around 81,180 new bladder cancer cases are likely to be diagnosed in the United States in 2022. Thus, with the rising burden of bladder cancer, the burden of urothelial cancer is also expected to increase. This in turn is likely to increase the demand for its treatment thereby propelling the market growth over the forecast period.
Additionally, various strategies adopted by the key market players are also supporting the market growth. For instance, in June 2020, Pfizer received the United States Food and Drug Administration approval for BAVENCIO. It has been approved as a first-line maintenance treatment among patients suffering from advanced/metastatic urothelial carcinoma. Furthermore, in April 2020, UroGen Pharma received the United States Food and Drug Administration approval for mitomycin gel (Jelmyto), which has been indicated for the treatment of low-grade upper tract urothelial cancer. Therefore, increasing approvals from the United States Food and Drug Administration and product launches by key players are expected to boost the market growth.
Thus, all aforementioned factors are expected to boost market growth in the North American region over the forecast period.
To understand geography trends, Download Sample Report
Competitive Landscape
The urothelial cancer drug market is consolidated. However, it is expected to grow rapidly in the next couple of years with intense competition among the players and a rising number of cases. Few key players are already being observed adopting strategies, such as collaboration for the development of therapies and drugs, which may make the urothelial cancer drugs market crowded with new products in the next couple of years. Some of the major players in the urothelial cancer drugs market are Merck & Co. Inc., F Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AstraZeneca PLC, and Novartis AG, among others.
Major Players
Merck & Co. Inc.
Bristol-Myers Squibb Company
Novartis AG
F Hoffmann-La Roche AG
AstraZeneca PLC
Recent Developments
- In August 2021, Merck announced a label update for KEYTRUDA, Merck’s anti-PD-1 therapy, for its indication in first-line advanced urothelial carcinoma (bladder cancer) in the United States. The United States Food and Drug Administration (USFDA) converted this indication from an accelerated to a full (regular) approval.
- In August 2021, the United States Food and Drug Administration (USFDA) approved nivolumab (Opdivo) for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence after undergoing radical resection, irrespective of prior neoadjuvant chemotherapy, nodal involvement or PD-L1 status.
Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Emergence and Priority of Targeted Therapy Among Biopharmaceutical Companies
4.2.2 Growing Burden of Urothelial Cancer
4.2.3 Increasing Awareness on Bladder Diseases and Available Therapies
4.3 Market Restraints
4.3.1 Side Effects Associated with Drugs
4.4 Industry Attractiveness - Porter's Five Forces Analysis
4.4.1 Bargaining Power of Buyers/Consumers
4.4.2 Bargaining Power of Suppliers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value – USD Million)
5.1 By Treatment
5.1.1 Chemotherapy
5.1.2 Immunotherapy
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia Pacific
5.2.4 Middle East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Merck & Co. Inc.
6.1.2 F Hoffmann-La Roche AG
6.1.3 Bristol-Myers Squibb Company
6.1.4 AstraZeneca PLC
6.1.5 Novartis AG
6.1.6 GlaxoSmithKline PLC
6.1.7 Sanofi SA
6.1.8 Eisai Co. Ltd
6.1.9 Astellas Pharma
6.1.10 UroGen Pharma
6.1.11 Pfizer Inc.
6.1.12 Genentech USA Inc.
*List Not Exhaustive7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Frequently Asked Questions
What is the study period of this market?
The Global Urothelial Cancer Drugs Market market is studied from 2019 - 2027.
What is the growth rate of Global Urothelial Cancer Drugs Market?
The Global Urothelial Cancer Drugs Market is growing at a CAGR of 15.5% over the next 5 years.
Which region has highest growth rate in Global Urothelial Cancer Drugs Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Urothelial Cancer Drugs Market?
North America holds highest share in 2021.
Who are the key players in Global Urothelial Cancer Drugs Market?
Merck & Co. Inc., Bristol-Myers Squibb Company, Novartis AG, F Hoffmann-La Roche AG, AstraZeneca PLC are the major companies operating in Global Urothelial Cancer Drugs Market.
